← Comparing 2 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
APOE4-Specific Lipidation Enhancement Therapy (APOE) — 0.84 Closed-loop transcranial focused ultrasound to restore hippo (PVALB) — 0.71 SASP-Mediated Complement Cascade Amplification (C1Q/C3) — 0.70 Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa (APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)) — 0.70 Closed-loop tACS targeting EC-II SST interneurons to block t (SST) — 0.70 Closed-loop focused ultrasound targeting EC-II SST interneur (SST) — 0.70 Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 (BDNF) — 0.69 TREM2-Dependent Microglial Senescence Transition (TREM2) — 0.69 Closed-loop transcranial focused ultrasound with 40Hz gamma (PVALB) — 0.69 Gamma entrainment therapy to restore hippocampal-cortical sy (SST) — 0.68 Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna (BDNF) — 0.68 H2: Indole-3-Propionate (IPA) as the Actual Neuroprotective (PXR (NR1I2), IDO1) — 0.68 CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Wind (sTREM2/membrane-TREM2/ADAM10) — 0.67 Closed-loop tACS targeting EC-II PV interneurons to suppress (PVALB) — 0.67 Nutrient-Sensing Epigenetic Circuit Reactivation (SIRT1) — 0.67 Beta-frequency entrainment therapy targeting PV interneuron- (SST) — 0.67 Transcriptional Autophagy-Lysosome Coupling (FOXO1) — 0.66 Stathmin-2 Splice Switching to Prevent Axonal Degeneration A (STMN2 (stathmin-2), PTBP1/PTBP2) — 0.66 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro (ACSL4) — 0.66 Closed-loop tACS targeting EC-II parvalbumin interneurons to (PVALB) — 0.66 STMN2 Restoration as a Prerequisite for Axon Growth After TD (STMN2) — 0.66 Temporal SPP1 Inhibition During Critical Windows (SPP1) — 0.65 Selective Acid Sphingomyelinase Modulation Therapy (SMPD1) — 0.65 Beta-Hydroxybutyrate Receptor (HCAR2) Signaling Links Ketone (HCAR2) — 0.65 Dual-Receptor Antibody Shuttling (?) — 0.64 Closed-loop transcranial alternating current stimulation to (SST) — 0.64 TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen (TREM2) — 0.64 SASP-Driven Microglial Metabolic Reprogramming in Synaptic P (HK2/PFKFB3) — 0.64 TREM2-Dependent Microglial Phagocytosis Acts as a Strain Sel (TREM2) — 0.64 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.63
Add
|
× Transglutaminase-2 Cross- × Low Complexity Domain Cro
TGM2 · neurodegeneration · therapeutic
Composite 0.488
Price $0.49
Evidence For 12
Evidence Against 4
The Transglutaminase-2 (TG2) Cross-Linking Inhibition Strategy targets the enzymatic mechanism responsible for creating covalent isopeptide bonds between aggregation-prone proteins in neurodegenerative diseases. TG2 catalyzes the formation of Nε-(γ-glutamyl)lysine cross-links between glutamine and lysine residues, creating irreversible protein-protein bonds that stabilize pathological aggregates of tau, α-synuclein, and huntingtin. By selectively inhibiting TG2's cross-linking activity at diseas
TGM2 · neurodegeneration · mechanistic
Composite 0.415
Price $0.42
Evidence For 11
Evidence Against 7
**Molecular Mechanism and Rationale**
Transglutaminase 2 (TGM2) represents a critical enzyme in the pathological cascade leading to neurodegeneration through its ability to catalyze the cross-linking of proteins containing low complexity domains (LCDs), particularly TDP-43 (TAR DNA-binding protein 43). TGM2 belongs to a family of calcium-dependent enzymes that catalyze the formation of covalent bonds between glutamine and lysine residues, creating stable ε-(γ-glutamyl)lysine cross-links that re
Verdict Summary 9/10
dimensions won
Transglutaminase-2 Cross-Linking Inhibit
1/10
dimensions won
Low Complexity Domain Cross-Linking Inhi
Radar Chart — 10 Dimensions
Score Breakdown
Dimension Transglutaminase-2 Cross-Linki Low Complexity Domain Cross-Li Mechanistic 0.750 0.400 Evidence 0.600 0.300 Novelty 0.700 0.600 Feasibility 0.800 0.700 Impact 0.700 0.500 Druggability 0.850 0.800 Safety 0.650 0.400 Competition 0.750 0.800 Data 0.700 0.400 Reproducible 0.750 0.400
Evidence Transglutaminase-2 Cross-Linking Inhibition Strategy Supporting Evidence TG2-mediated isopeptide bonds are found in 100% of AD neurofibrillary tangles and 85% of Lewy bodies PMID:12427850 J Neuropathol Exp Neurol 2002 TG2 cross-links tau at Q276/Q288 in the MTBR domain, creating protease-resistant seeds with enhanced seeding activity PMID:29769264 J Biol Chem 2018 TG2 creates heterologous tau-α-synuclein cross-links, potentially explaining co-pathology overlap PMID:31296608 Acta Neuropathol Commun 2019 Cysteamine (TG2 inhibitor) reduces protein aggregation and improves behavior in HD and AD mouse models PMID:16624915 Nat Med 2006 ERW1041E selectively inhibits TG2, reduces isopeptide bonds, and extends lifespan in HD R6/2 mice PMID:23390102 PLoS One 2013 Contradicting Evidence TG2 has GTPase signaling and scaffolding functions beyond cross-linking; inhibition may disrupt beneficial non-enzymatic PMID:27184831 Brain-penetrant selective TG2 inhibitors remain in early development with limited in vivo pharmacokinetic data PMID:31476489 TG2 cross-linking may represent a late-stage epiphenomenon of AD rather than a causative driver of early pathology PMID:25824747 Low Complexity Domain Cross-Linking Inhibition Supporting Evidence TGM2 activity is elevated 3-8 fold in ALS patient spinal cord and colocalizes with TDP-43 inclusions PMID:31515476 Acta Neuropathol Commun 2019 TGM2-mediated cross-linking of TDP-43 LCD residues Q331/Q343/Q360/Q386 identified in patient aggregates by mass spectrom PMID:30389657 J Biol Chem 2018 TGM2 cross-linking converts liquid-like condensates to gel-like aggregates with reduced molecular exchange (FRAP) PMID:33073191 EMBO J 2020 TGM2 activity increases precede TDP-43 aggregation in presymptomatic ALS mouse models PMID:29146756 Hum Mol Genet 2018 GTP-competitive TGM2 inhibitors reduce protein cross-linking in neuronal cultures under oxidative stress PMID:28724645 PLoS One 2017 Contradicting Evidence TGM2 has essential neuroprotective roles in wound healing and neuronal survival signaling through GTPase activity PMID:27553685 TGM2 knockout mice show impaired phagocytic clearance of apoptotic neurons, potentially worsening neurodegeneration PMID:17320118 Cross-linking may not be the primary driver; LCD amyloid fiber formation through beta-sheet stacking occurs independentl PMID:30279529 Debate Excerpts Transglutaminase-2 Cross-Linking Inhibition Strate 4 rounds · quality: 0.35
Theorist I notice there's a significant mismatch between the task and the provided literature. You've asked me to generate therapeutic hypotheses for neurodegeneration, but the provided literature consists ent...
Skeptic You are absolutely correct in your assessment. There is a fundamental mismatch between the task of critiquing therapeutic hypotheses for neurodegeneration and the provided literature, which consists e...
Domain Expert ## Critical Assessment: Complete Literature-Hypothesis Mismatch
You are absolutely correct in identifying this fundamental problem. As a domain expert in neuroscience and drug development, I must emp...
Synthesizer ```json
{
"ranked_hypotheses": [
{
"title": "Cannot Generate Hypotheses",
"description": "No neurodegeneration-related hypotheses can be synthesized due to complete literature mismat...
Low Complexity Domain Cross-Linking Inhibition 4 rounds · quality: 0.54
Theorist # Novel Therapeutic Hypotheses for TDP-43 Phase Separation in ALS-FTD
## Hypothesis 1: Arginine Methylation Enhancement Therapy
**Target:** PRMT1/CARM1 (Protein Arginine Methyltransferases)
**Descri...
Theorist # Novel Therapeutic Hypotheses for TDP-43 Phase Separation in ALS-FTD
## Hypothesis 1: Arginine Methylation Enhancement Therapy
**Target:** PRMT1/CARM1 (Protein Arginine Methyltransferases)
**Descri...
Skeptic # Critical Evaluation of TDP-43 Phase Separation Therapeutic Hypotheses
## Hypothesis 1: Arginine Methylation Enhancement Therapy
### Specific Weaknesses:
1. **Oversimplified mechanism**: The hypoth...
Skeptic # Critical Evaluation of TDP-43 Phase Separation Therapeutic Hypotheses
## Hypothesis 1: Arginine Methylation Enhancement Therapy
### Specific Weaknesses:
1. **Oversimplified mechanism**: The hypoth...
Price History Overlay
Shared Evidence
3 paper(s) cited by multiple hypotheses — shared evidence strengthens or challenges convergent claims.
11% Evidence Overlap
26 Total Unique Papers
3 Shared Papers
Knowledge Graph Comparison
Transglutaminase-2 Cross-Linking Inhibit
43 edges
Top Node Types gene 38
hypothesis 5
Top Relations co_discussed 24
co_associated_with 11
targets 5
associated_with 2
implicated_in 1
Low Complexity Domain Cross-Linking Inhi
103 edges
Top Node Types gene 90
hypothesis 7
protein 3
pathway 3
Top Relations co_discussed 49
co_associated_with 20
participates_in 8
implicated_in 7
associated_with 7